Related Experiment Video
Updated: Aug 7, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications
1Department of Urology, Hospital Barmherzige Brüder, Munich, Germany.
Urologia Internationalis
|February 24, 2006
Summary
Zoledronic acid effectively manages metastatic bone disease in advanced prostate cancer and renal cell carcinoma (RCC) patients. It delays skeletal-related events (SREs) and improves quality of life, offering a breakthrough in treatment.
Area of Science:
- Oncology
- Pharmacology
- Bone Metastasis Management
Background:
- Biphosphonates are investigated for therapeutic benefits in advanced prostate cancer and renal cell carcinoma (RCC).
- Their role in managing ADT-induced osteoporosis and skeletal-related events (SREs) in metastatic bone disease is crucial.
- Understanding the proposed mechanisms of action is key to optimizing their use.
Purpose of the Study:
- To review recent findings on the therapeutic applications of biphosphonates in advanced prostate cancer and RCC.
- To discuss the efficacy of biphosphonates in preventing osteoporosis and SREs.
- To provide an overview of the proposed modes of action for biphosphonates.
Main Methods:
- A comprehensive literature search was conducted using PubMed.
- Included documented publications and abstracts from scientific meetings.
Main Results:
- Zoledronic acid is the only biphosphonate demonstrated to delay SREs in RCC and prostate cancer patients.
- Zoledronic acid effectively counteracts cancer treatment-induced osteoporosis in men with prostate cancer.
- In vitro and in vivo studies suggest potential antitumor activity for biphosphonates, warranting further clinical investigation.
Conclusions:
- Zoledronic acid represents a significant advancement in managing metastatic bone disease for advanced prostate cancer and RCC patients.
- It substantially enhances patients' quality of life and significantly extends the time to the first SRE.
- While not statistically significant, a positive trend in survival was observed.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Urinary Tract Calculi III: Medical Management
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...